https://www.emmausmedical.com/2019-09-17weekly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-partners-with-dms-pharmaceutical-group-to-provide-endari-l-glutamine-oral-powder-to-military-personnel-and-beneficiaries-for-treatment-of-sickle-cell-disease-1582019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-phase-3-sickle-cell-disease-trial-data-included-in-2015-highlights-of-ash-program-1132019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/sickle-cell-disease-association-of-america-inc-partners-with-emmaus-life-sciences-inc-1522019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-opening-of-office-in-new-york-to-support-endari-launch-1512019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-at-cavendish-global-health-impact-forum-1172019-09-17monthly1.0https://www.emmausmedical.com/content/overview/overview-72019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-support-of-sickle-cell-disease-legislation-1572019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-marks-progression-of-phase-3-sickle-cell-disease-clinical-trial-942019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/fda-advisory-committee-recommends-approval-of-endari-from-emmaus-life-sciences-for-the-treatment-of-sickle-cell-disease-1402019-09-17monthly1.0https://www.emmausmedical.com/content/overview/leadership/management-team/management-team-142019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-receives-notice-of-fda-pdufa-date-for-investigational-l-glutamine-treatment-for-sickle-cell-disease-1332019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-phase-3-sickle-cell-disease-clinical-trial-data-1152019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-inc-receives-notice-of-allowance-for-us-patent-for-use-of-l-glutamine-in-treatment-of-diverticulosis-1372019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-appoints-new-members-to-board-of-directors-1112019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-participate-in-the-piper-jaffray-healthcare-conference-1662019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-additional-new-data-from-its-phase-3-sickle-cell-disease-trial-at-57th-annual-ash-meeting-1212019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-closing-of-75-million-private-placement-1062019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-abstract-of-completed-phase-3-sickle-cell-disease-trial-at-9th-annual-sickle-cell-and-thalassaemia-advanced-conference-in-london-1192019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/sickle-cell-treatment-approved-for-phase-iii-clinical-trial-772019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-positive-top-line-results-of-its-phase-3-clinical-trial-for-sickle-cell-disease-1102019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-availability-of-endari-l-glutamine-oral-powder-for-sickle-cell-disease-in-the-united-states-1472019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-ceo-yutaka-niihara-md-issues-statement-in-connection-with-status-of-company-s-phase-iii-fda-sickle-cell-treatment-trials-972019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-launches-its-commercial-co-payment-assistance-program-for-endari-1682019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-strengthens-its-finance-and-operations-leadership-to-support-commercialization-of-endari-1562019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-the-new-england-journal-of-medicine-has-published-the-phase-3-trial-results-of-endari-l-glutamine-oral-powder-in-sickle-cell-disease-1552019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/mynd-analytics-and-emmaus-life-sciences-announce-merger-and-spin-off-transaction-1672019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-announces-completion-of-enrollment-for-its-phase-3-sickle-cell-disease-trial-982019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-partners-with-taiba-healthcare-to-commercialize-endari-for-sickle-cell-disease-in-the-middle-east-and-north-africa-region-1692019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/european-commission-grants-orphan-medicinal-product-designation-for-emmaus-medical-s-sickle-cell-treatment-912019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/endari-update-1452019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/mytomorrows-and-emmaus-life-sciences-inc-to-collaborate-on-early-access-program-for-sickle-cell-disease-treatment-in-the-eu-turkey-middle-east-and-south-america-1462019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-new-cfo-and-ema-opinion-1742019-09-17monthly1.0https://www.emmausmedical.com/content/contact-us/contact-us-642019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-issues-statement-in-response-to-announcement-by-afh-holding-and-advisory-952019-09-17monthly1.0https://www.emmausmedical.com/content/products/zorbtive/andnbsp-302019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-joins-new-sickle-cell-disease-coalition-issues-call-to-action-to-improve-treatment-and-care-1292019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-at-upcoming-investor-and-partnering-conferences-during-national-sickle-cell-awareness-month-1182019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-sideline-sickle-cell-campaign-teams-up-with-sctpn-for-world-sickle-cell-day-event-on-june-19-1762019-09-17monthly1.0https://www.emmausmedical.com/content/overview/corporate-governance/corporate-governance-872019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-completes-20-million-private-placement-1312019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-sickle-cell-treatment-receives-positive-opinion-on-pediatric-investigation-plan-from-european-medicines-agency-1442019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-secures-funding-to-advance-sickle-cell-disease-1242019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emd-serono-inc-782019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-to-present-at-6th-annual-onemedforum-992019-09-17monthly1.0https://www.emmausmedical.com/content/for-patients/short-bowel-syndrome/short-bowel-syndrome-592019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/dr-henry-a-mckinnell-jr-former-pfizer-ceo-joins-emmaus-medical-inc-board-of-directors-612019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-a-leader-in-sickle-cell-disease-treatment-signs-agreement-with-mckesson-to-expand-distribution-network-for-endari-l-glutamine-oral-powder-1592019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-wins-sweeping-summary-judgment-victory-in-suit-against-afh-holding-and-advisory-and-amir-heshmatpour-1022019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-reappointment-of-dr-yutaka-niihara-as-ceo-1232019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/nfl-broadcaster-solomon-wilcots-and-emmaus-life-sciences-kick-off-sideline-sickle-cell-campaign-during-national-minority-health-month-1712019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/mynd-analytics-and-emmaus-life-sciences-announce-availability-of-definitive-joint-proxy-statement-prospectus-relating-to-merger-and-spin-off-transaction-1752019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-issues-statement-in-response-to-announcement-by-afh-holding-and-advisory-1002019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-fda-acceptance-of-ind-application-for-clinical-study-of-l-glutamine-for-treatment-of-diverticulosis-1532019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-presentation-of-abstract-at-the-2018-american-society-of-hematology-annual-meeting-1642019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-seek-marketing-approval-for-first-new-sickle-cell-disease-treatment-in-nearly-20-years-expects-to-submit-new-drug-application-to-fda-in-september-1282019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/the-us-food-and-drug-administration-approves-endari-l-glutamine-oral-powder-the-first-and-only-treatment-for-sickle-cell-disease-in-pediatric-patients-and-first-in-nearly-20-years-for-adults-1412019-09-17monthly1.0https://www.emmausmedical.com/content/overview/mission/mission-82019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-a-leader-in-sickle-cell-disease-treatment-to-sponsor-the-46th-annual-national-sickle-cell-disease-association-of-america-convention-in-baltimore-1622019-09-17monthly1.0https://www.emmausmedical.com/content/overview/leadership/board-of-directors/board-of-directors-152019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-announces-completion-of-all-patient-visits-for-its-phase-3-clinical-trial-for-treatment-of-sickle-cell-disease-1082019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-inc-receives-japanese-patent-for-use-of-l-glutamine-in-treatment-of-diverticulosis-1342019-09-17monthly1.0https://www.emmausmedical.com/content/overview/corporate-compliance/corporate-compliance-162019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-submits-new-drug-application-for-sickle-cell-disease-treatment-1302019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-at-maxim-groups-sickle-cell-disease-investor-conference-on-november-20-1202019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-receives-30m-debt-investment-from-gpb-capital-1482019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-initiation-of-its-diverticulosis-study-1772019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/mynd-analytics-and-emmaus-life-sciences-report-progress-on-merger-and-spin-off-transaction-1782019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/mynd-analytics-and-emmaus-life-sciences-stockholders-approve-merger-and-spin-off-transactions-1792019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-completes-merger-1802019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-hiring-of-new-endari-product-manager-1812019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-receives-notice-of-nasdaq-delisting-following-merger-with-mynd-analytics-1822019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-brings-sideline-sickle-cell-campaign-to-dallas-for-participation-in-annual-warriors-convention-1832019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-details-financial-benefits-from-recent-merger-including-improved-balance-sheet-and-reduced-debt-service-1842019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-reiterates-financial-benefits-from-recent-merger-1852019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-reports-sharply-improved-2019-second-quarter-financial-results-1862019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-protocol-for-study-of-pharmaceutical-grade-l-glutamine-for-the-treatment-of-diabetes-1872019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-host-sideline-sickle-cell-community-town-hall-with-asap-and-fscdr-in-south-florida-1882019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-adds-oncology-supply-as-distributor-1892019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-granted-european-patent-for-use-of-pharmaceutical-grade-l-glutamine-in-treating-diverticulosis-1902019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-be-delisted-from-nasdaq-stock-market-following-hearing-1912019-09-17monthly1.0https://www.emmausmedical.com/content/overview/letters/ceo-letter-sep-10-2019-1932019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-signs-licensing-agreement-with-tokyo-based-regenerative-medicine-company-cellseed-1272019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-s-sickle-cell-treatment-receives-positive-opinion-for-orphan-drug-status-from-european-medicines-agency-882019-09-17monthly1.0https://www.emmausmedical.com/content/terms-and-privacy/terms-of-use-722019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-a-leader-in-sickle-cell-disease-treatment-signs-agreement-with-cardinal-health-to-solidify-distribution-network-for-endari-l-glutamine-oral-powder-1612019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-medicaid-coverage-of-endari-l-glutamine-oral-powder-for-sickle-cell-disease-in-the-united-states-1492019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-management-promotions-1262019-09-17monthly1.0https://www.emmausmedical.com/content/pipeline/sickle-cell-disease/sickle-cell-disease-432019-09-17monthly1.0https://www.emmausmedical.com/content/products/endari/endari-272019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-a-leader-in-sickle-cell-disease-treatment-to-sponsor-the-12th-annual-sickle-cell-disease-and-thalassaemia-ascat-conference-in-london-1632019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-appoints-durbin-as-distribution-partner-1222019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-medical-inc-announces-availability-of-endari-for-treatment-of-sickle-cell-disease-1432019-09-17monthly1.0https://www.emmausmedical.com/content/news/events/event-1-622019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-receives-validation-from-european-medicines-agency-on-marketing-authorization-application-for-sickle-cell-disease-treatment-xyndari-oral-glutamine-1502019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-inc-announces-fda-advisory-committee-meeting-for-endari-for-sickle-cell-disease-1392019-09-17monthly1.0https://www.emmausmedical.com/content/pipeline/cell-sheet-engineering/cell-sheet-engineering-832019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/former-fda-official-tim-cote-joins-emmaus-medical-as-regulatory-advisor-1012019-09-17monthly1.0https://www.emmausmedical.com/content/for-patients/sickle-cell-disease/sickle-cell-disease-582019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-announces-new-board-members-1252019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/yutaka-niihara-md-mph-ceo-of-emmaus-appointed-executive-chairman-of-generex-biotechnology-corporation-1362019-09-17monthly1.0https://www.emmausmedical.com/content/career/career-1092019-09-17monthly1.0https://www.emmausmedical.com/content/pipeline/diverticulosis/diverticulosis-1722019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-signs-agreement-with-express-scripts-1702019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-to-present-phase-3-sickle-cell-disease-trial-data-at-56th-american-society-of-hematology-annual-meeting-1122019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/news-medicalnet-insights-from-industry-962019-09-17monthly1.0https://www.emmausmedical.com/content/news/media-contacts/media-contacts-632019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-cancels-stock-held-by-afh-holding-and-advisory-and-amir-heshmatpour-1042019-09-17monthly1.0https://www.emmausmedical.com/content/terms-and-privacy/privacy-policy-732019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-new-drug-application-for-sickle-cell-disease-accepted-for-review-by-fda-1322019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-a-leader-in-sickle-cell-disease-treatment-to-present-at-the-seventh-annual-sickle-cell-disease-therapeutics-conference-in-new-york-city-on-september-13th-1602019-09-17monthly1.0https://www.emmausmedical.com/content/news/press-releases/emmaus-life-sciences-inc-to-present-results-of-phase-3-study-of-endaritm-l-glutamine-oral-powder-at-59th-american-society-of-hematology-annual-meeting-1422019-09-17monthly1.0